Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Intranasal esketamine plus antidepressant deflects relapse

Key clinical point: Patients with depression who had achieved remission were significantly less likely to relapse when esketamine nasal spray was added to their oral antidepressant.

Major finding: Relapses occurred in 26.7% of patients in the esketamine and antidepressant group, compared with 45.3% of the placebo group.

Study details: The data come from the SUSTAIN-1 trial, a multicenter, double-blind, randomized withdrawal study of 297 adults with stable remission of depression.

Disclosures: Dr. Daly and several coauthors are employees of Janssen Research and Development, which funded the study.


Daly E et al. JAMA Psychiatry. 2019 Jun 5. doi: 10.1001/jamapsychiatry.2019.1189.